KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

References

• 1. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell 170(1), 17–33 (2017).
  Medline CASGoogle Scholar
• 2. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19(8), 533–552 (2020).
  Medline CASGoogle Scholar
• 3. Network Cancer Genome Atlas Research. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511), 543–550 (2014).
  MedlineGoogle Scholar
• 4. Network Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330–337 (2012).
  MedlineGoogle Scholar
• 5. Network Cancer Genome Atlas Research. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2), 185–203.e13 (2017).
  MedlineGoogle Scholar
• 6. Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12C somatic mutations across race, sex, and cancer type. N. Engl. J. Med. 384(2), 185–187 (2021).
  MedlineGoogle Scholar
• 7. Veluswamy R, Mack PC, Houldsworth J, Elkhouly E, Hirsch FR. KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing. J. Mol. Diagn. 23(5), 507–520 (2021).
  Medline CASGoogle Scholar
• 8. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890–2896 (2007).
  Medline CASGoogle Scholar
• 9. Jones RP, Sutton PA, Evans JP et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116(7), 923–929 (2017).
  Medline CASGoogle Scholar
• 10. Canon J, Rex K, Saiki AY et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781), 217–223 (2019).
  Medline CASGoogle Scholar
• 11. Hong DS, Fakih MG, Strickler JH et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383(13), 1207–1217 (2020).
  Medline CASGoogle Scholar
• 12. IASLC. Sotorasib shows early activity against KRAS G12C mutant NSCLC. https://www.iaslc.org/iaslc-news/ilcn/sotorasib-shows-early-activity-against-kras-g12c-mutant-nsclc
  Google Scholar
• 13. Hallin J, Engstrom LD, Hargis L et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10(1), 54–71 (2020).
  Medline CASGoogle Scholar
• 14. Jänne PA, Rybkin II, Spira AI et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small-cell lung cancer (NSCLC) harboring KRAS G12C mutation. Eur. J. Cancer 138, S1–S2 (2020).
  MedlineGoogle Scholar
• 15. Johnson ML, Ou SHI, Barve M et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation. Eur. J. Cancer 138, S2 (2020).
  Google Scholar
• 16. Amodio V, Yaeger R, Arcella P et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10(8), 1129–1139 (2020).
  Medline CASGoogle Scholar
• 17. Ryan MB, Fece de la Cruz F, Phat S et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition. Clin. Cancer Res. 26(7), 1633–1643 (2020).
  Medline CASGoogle Scholar
• 18. Misale S, Fatherree JP, Cortez E et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin. Cancer Res. 25(2), 796–807 (2019).
  Medline CASGoogle Scholar
• 19. Tanaka N, Lin JJ, Li C et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. doi:10.1158/2159-8290.CD-21-0365 (2021) (Epub ahead of print).
  MedlineGoogle Scholar
• 20. Mark Awad. AACR Annual Meeting 2021 Online Proceedings and Itinerary Planner. Dana-Farber Cancer Institute, MA, USA. https://www.abstractsonline.com/pp8/#!/9325/presentation/4751
  Google Scholar